Assertio Therapeutics (ASRT) has provided an announcement.
Assertio Holdings, Inc. has appointed Brendan P. O’Grady as the new CEO, effective May 29, 2024. He brings extensive experience from his previous roles, including CEO of Glenmark Pharmaceuticals’ Global Formulations Business and executive positions at Teva Pharmaceutical Industries. Alongside his CEO role, O’Grady will also join the Board of Directors. His compensation package includes a base salary of $850,000, potential cash bonuses, stock options, and restricted stock units, with provisions for additional benefits under certain termination conditions.
For detailed information about ASRT stock, go to TipRanks’ Stock Analysis page.
